[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Friendship Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":630},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,67,0,25,[9,41,73,97,123,145,172,189,210,233,262,293,318,345,366,391,420,441,462,484,506,535,561,588,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652775","hcc-risk-prediction-model-based-on-multimodal-data-in-chronic-hepatitis-b-100652775",false,"NCT07780357","HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B","Development and Application of an HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B","Inclusion Criteria:\n\n1. Aged ≥18 years, both sexes eligible.\n2. Diagnosed with hepatitis B-related liver fibrosis or cirrhosis based on clinical assessment or liver histopathology.\n3. Undergoing antiviral treatment.\n4. Follow-up duration between 0.5- 5 years.\n5. Availability of baseline data and at least two longitudinal follow-up visits.\n6. Clinical outcomes during the follow-up period are traceable.\n\nExclusion Criteria:\n\n1. Diagnosis of Hepatocellular carcinoma (HCC) or liver transplantation at baseline or within 6 months after baseline\u002Fenrollment.\n2. Coexisting other chronic liver diseases, such as genetic\u002Fmetabolic liver diseases, drug-induced liver injury, or severe steatotic liver disease.\n3. Coexisting other malignancies (except those considered cured).","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","We propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis\u002Fcirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.",[25],"Hepatocellular Carcinoma (HCC)",[27],"HCC, Risk Prediction Model, Multimodal Data, Chronic Hepatitis B","NOT_YET_RECRUITING","2026-08-19",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-08-20",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Beijing Friendship Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":40},"100576688","fluorescence-guided-laparoscopic-endoscopic-cooperative-sentinel-lymph-node-navigation-surgery-strategy-for-early-gastric-cancerideal-stage-2b-100576688","NCT06788548","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b）","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial Study","FLECSS","Inclusion Criteria:\n\n* 1\\) Patients aged 18-80 years, regardless of gender. 2) Patients with Eastern Cooperative Oncology Group (ECOG) score ≤ 2 and American Society of Anesthesiologists (ASA) score ≤ 2 who are candidates for a curative D2 gastrectomy.\n\n  3\\) Patients without prior gastrointestinal surgery, chemotherapy, or radiotherapy.\n\n  4\\) Patients with normal liver, kidney, heart, lung, and bone marrow function (GPT × 109 \u002FL, PLT\\>109 \u002FL).\n\n  5\\) Patients capable of understanding and adhering to the research protocol. 6) Patients who can provide written informed consent, either personally or through legal representative.\n\n  7\\) Patients with cT1N0M0 gastric cancer or after non-curative ESD resection, according to the UICC TNM staging system, 8th edition.\n\nExclusion Criteria:\n\n* 1\\) Patients with a contraindication for gastroscopy. 2) Patients with uncontrollable diseases, such as coagulation disorders, epilepsy, central nervous system diseases or mental disorders, cardiopulmonary insufficiency, unstable angina, myocardial infarction, a cerebrovascular accident that occurred within 6 months, and other surgical contraindications.\n\n  3\\) Patients unable to undergo general anesthesia or surgical treatment due to conditions related to other organs, or unwilling to undergo surgery.\n\n  4\\) Patients with gastric stump cancer, recurrent gastric cancer, multiple primary malignant tumors in the abdominopelvic cavity, or a history of other malignant tumors within the previous 5 years.\n\n  5\\) Pregnant or lactating women. 6) Participants enrolled in other clinical trials. 7) Patients with undeterminable tracer staining range or contraindications to tracer use.\n\n  8\\) Patients who fail to receive or fail ESD therapy. 9) Patients who meet the absolute indication of ESD.","80 Years",{"count":51,"type":21},312,"INTERVENTIONAL",[54],"NA","The main treatment for early gastric cancer (EGC) include endoscopic submucosal dissection (ESD) and radical gastrectomy. However, appropriate treatment for patients who exceed the absolute indications and noncurative resection of ESD remains unestablished. Sentinel node navigation surgery (SNNS) enables limited lymph node resection, thereby facilitating function-preserving gastrectomy (FPG) and improving quality of life (QoL). SNNS seems to be the promising solution according to previous study, however evidence-based medicine was lacking. It is imperative to establish its safety and efficacy in patients with EGC. However, the optimal implementation of FPG remain unclear. Moreover, objective assessment of postoperative functional outcomes,remains limited.",[57],"Early Gastric Cancer",[57,59,60,61,62,63,64,65],"Sentinel Lymph Node","Basin Dissection","Laparoscopic surgery","Safety AND Efficacy","Fluorescence Guided","Laparoscopic-Endoscopic Cooperative Surgery","multicenter","RECRUITING",{"date":31,"type":32},{"date":69,"type":32},"2024-02-03",{"date":71,"type":21},"2029-12-30",{"name":38,"class":39},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100652760","liver-stiffness-changes-by-ilivtouch-to-predict-liver-related-events-in-mafld-100652760","NCT07777198","Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD","Exploring the Risk Prediction of Liver-Related Events in Metabolic-Associated Fatty Liver Disease Based on Changes in Liver Stiffness Values Measured by iLivTouch","MAFLD","Inclusion Criteria:\n\n1. Aged ≥18 years, both male and female.\n2. Clinically diagnosed with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and progressed to compensated advanced chronic liver disease (cACLD) according to the 2024 Chinese Guidelines for the Management of Metabolic-Associated (Non-Alcoholic) Fatty Liver Disease. cACLD is defined as baseline liver stiffness measurement (LSM1) ≥10 kPa based on the Baveno-VII consensus.\n3. At least two valid LSM measurements during follow-up, with an interval of no less than 12 months between the two measurements.\n\nExclusion Criteria:\n\n1. Co-existing other chronic liver diseases, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, etc.\n2. Weekly alcohol intake ≥210 g for men or ≥140 g for women.\n3. Occurrence of liver-related endpoint events within 6 months before or after obtaining the LSMC value.\n4. Hepatectomy or liver transplantation performed within 6 months before or after obtaining the LSMC value.\n5. Malignant neoplasm diagnosed within 6 months before or after obtaining the LSMC value.\n6. Presence of vascular liver disease, cystic fibrosis-related liver disease, sarcoidosis, polycystic liver disease, congenital or rare inherited liver disease, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure complicated by hepatic venous congestion.\n7. History of transjugular intrahepatic portosystemic shunt (TIPS).\n8. Acute hepatitis (alanine aminotransferase \\>5-fold upper limit of normal) or acute-on-chronic liver failure (ACLF) occurring at the time of LSM1 or LSMC measurement.\n9. Missing value of either LSM1 or LSMC.\n10. Any other conditions judged by investigators to be inappropriate for study participation.",{"count":82,"type":21},2303,"This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and their dynamic changes) acquired by domestic iLivTouch device for liver-related events (LREs) and all-cause mortality among MAFLD patients with compensated advanced chronic liver disease (cACLD), and to explore the prognostic value of dynamic LSM changes. The study population consists of adult patients aged ≥18 years of either sex, clinically diagnosed with MAFLD-related cACLD (defined as baseline LSM1 ≥10 kPa per Baveno-VII consensus), with at least two LSM measurements separated by ≥12-month follow-up interval, and without other confounding chronic liver diseases, excessive alcohol intake or predefined exclusion comorbidities. This study aims to answer several major questions: whether dynamic LSM parameters measured by iLivTouch can predict LREs and all-cause mortality in MAFLD-cACLD patients; whether risk of LREs differs between patients with significant LSMC decline and those without such decline in the resolved cACLD subgroup; whether liver-related mortality differs between resolved and persistent cACLD patients; and whether pharmacological interventions influence LRE risk and cACLD resolution.",[79],[86,87,88,89],"Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","Compensated Advanced Chronic Liver Disease (cACLD)","liver stiffness measurement","liver-related events","2026-08-17",{"date":34,"type":32},{"date":93,"type":21},"2026-09-17",{"date":95,"type":21},"2027-10-30",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100650626","a-retrospective-analysis-of-patients-with-gastroesophageal-reflux-disease-based-on-a-prospective-clinical-dataset-100650626","NCT07749989","A Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset","Establishing an Innovative Cohort of Chinese Patients With Gastroesophageal Reflux Disease Based on the Prospective Database of the National Clinical Research Center for Digestive Diseases: A Retrospective Study","Inclusion Criteria:\n\n* Aged between 18 and 90 years old.\n* Patients were required to present with at least one typical symptom of gastroesophageal reflux disease (GERD)-such as heartburn, regurgitation, or non-cardiac chest pain-and to have presented to Beijing Friendship Hospital for the evaluation and management of these symptoms.\n* Received treatment, including pharmacological therapy and anti-reflux surgery, at Beijing Friendship Hospital.\n* Voluntary signing of informed consent, agreeing to the use of clinical information for future research.\n\nExclusion Criteria:\n\n* Female patients who were pregnant or lactating.\n* Patients with significantly incomplete or missing critical clinical data.\n* Patients with an equivocal or unconfirmed diagnosis of GERD.\n* Current neurologic or cognitive impairment, which would preclude ability to obtain informed consent.\n* Refusal to participate in the study.","90 Years",{"count":106,"type":21},5000,"This retrospective, observational cohort study aimed to establish a comprehensive research cohort utilizing a large-scale prospective clinical registry. The primary objectives were to characterize the real-world demographic profiles, clinical features, psychological characteristics, and treatment patterns of Chinese patients with gastroesophageal reflux disease (GERD), as well as to evaluate post-treatment improvements in both GERD symptoms and psychological well-being. The study retrospectively enrolled approximately 5,000 patients with a confirmed diagnosis of GERD, with data derived from the prospective registry of the National Clinical Research Center for Digestive Diseases. Investigators systematically extracted data on baseline demographics, clinical presentations, objective diagnostic findings, preoperative psychological status, surgical complications, and longitudinal follow-up outcomes for all eligible patients. Ultimately, this study sought to provide high-quality, China-specific evidence to inform the precise phenotyping of GERD and to guide standardized, individualized clinical decision-making.",[109],"Gastroesophageal Reflux Disease",[109,111,112,113,114],"Retrospective Cohort","Surgical Treatment","Real-World Data","Quality of Life","2026-08-05",{"date":117,"type":32},"2026-08-06",{"date":119,"type":32},"2026-04-17",{"date":121,"type":21},"2027-05",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100650741","clinical-trial-to-evaluate-the-effectiveness-of-liver-shear-wave-quantization-detector-spleen-stiffness-value-in-the-diagnosis-of-esophageal-varices-100650741","NCT07753577","Clinical Trial to Evaluate the Effectiveness of Liver Shear Wave Quantization Detector Spleen Stiffness Value in the Diagnosis of Esophageal Varices","Inclusion Criteria:\n\n1. Age over 18 years old, male or female;\n2. patients with clinically diagnosed chronic liver disease, including hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, fatty liver disease, autoimmune liver disease, and alcoholic liver disease \\*;\n3. Liver stiffness measurement (LSM) ≥10kPa during screening or within one month before screening \\[4\\];\n4. able to communicate well with the investigators, understand and comply with the requirements of the study;\n5. Informed consent was signed voluntarily.\n\nExclusion Criteria:\n\n1. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥250 U\u002FL;\n2. complicated with jaundice (serum total bilirubin ≥50 μmol\u002FL);\n3. complicated with important organ diseases (except liver) or serious systemic diseases (such as malignant tumors and HIV);\n4. after liver transplantation or TIPS;\n5. after splenectomy, splenic embolization or other portasystemic shunts;\n6. patients with moderate-to-large amount of ascites;\n7. unstable condition in the acute stage of esophageal variceal bleeding;\n8. combined with liver malignant tumors;\n9. patients with non-cirrhotic portal hypertension, Budd-Chiari syndrome and other hepatic vascular diseases; Acute or chronic portal vein thrombosis;\n10. unhealed wounds or scars in the left abdomen were not suitable for ultrasound examination;\n11. pregnant women;\n12. Other conditions judged by the investigators as not suitable for participating in the study.",{"count":130,"type":21},246,"1 Month","Esophageal variceal bleeding is one of the serious and life-threatening complications of chronic liver disease (CLD). Studies have shown that the prevalence of esophageal varices (EV) in patients with liver cirrhosis is about 50%-60%. The annual incidence of variceal bleeding in these patients is about 5%-15%, and the rebleeding rate can reach 30%-40% within 6 weeks after the first bleeding. The 6-week mortality related to variceal bleeding is as high as 10%-20%, which seriously threatens the life safety of patients with liver disease. Clinically, esophagogastroduodenoscopy (EGD) is the gold standard for the diagnosis and grading of esophageal varices. However, EGD is an invasive examination, which has certain application limitations such as related complications and high cost, which limits the promotion and application of this technology.\n\nTherefore, there is an urgent need for an accurate, convenient and non-invasive method for esophageal varices. To address this clinical pain point, Baveno VII guidelines state that spleen stiffness measurement (SSM) based on vibration-controlled transient elastography (TE) can be used as a noninvasive marker to predict esophageal varices (EV). Several studies have shown that SSM measured by TE has good diagnostic performance in relation to the occurrence and severity of esophageal varices. A study involving 191 patients with liver disease showed that spleen stiffness was significantly higher in patients with varices than in those without varices (63.69 vs 47.78 kPa, P\\\u003C0.0001), and the AUC of SSM for the diagnosis of EV was 0.74. In another study involving 260 patients with chronic liver disease, the AUC of SSM was 0.728 (95% CI: 0.665-0.791) for EV and 0.780 (95% CI: 0.714-0.846) for high-risk varix (HRV). The above results indicate that SSM has good clinical value in the prediction of EV.\n\nPro9000X, a liver function shear wave quantization detector based on vibration control TE, has been developed by Wuxi Hisiel Medical Technology Co., LTD. The device integrates ultrasound image positioning and TE function, aiming to achieve rapid, quantitative and non-invasive detection of liver stiffness measurement (LSM) and SSM. The results of EGD examination were used as the gold standard to evaluate the diagnostic performance of the spleen stiffness value detected by Pro9000X in patients with chronic liver disease, and the main evaluation indicators were the sensitivity and specificity of EV diagnosis. Secondary evaluation included AUROC, optimal cut-off value and diagnostic value of high-risk EV.",[134,135,136,137],"Chronic Liver Diseases","Spleen Stiffness","Esophageal Varices","Diagnostic Performance Study","2026-08-04",{"date":140,"type":32},"2026-08-07",{"date":34,"type":21},{"date":143,"type":21},"2026-10-30",{"name":38,"class":39},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":52,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":40},"100483663","phase-4-opioid-free-anesthesia-on-the-quality-of-early-recovery-100483663","NCT05577962","Opioid Free Anesthesia on the Quality of Early Recovery","The Effect of Opioid-free Anesthesia Protocol on the Early Quality of Recovery After Thyroidectomy (TOFA Trial): Study Protocol for a Prospective, Monocentric, Randomized, Single-blinded Trial","opioid-free","Inclusion Criteria\n\n* Patients undergoing elective thyroidectomy under general anesthesia\n* \\>18 year old\n* The informed consent form has been signed\n* American Society of Anesthesiologists (ASA) anesthesia grade I - II\n\nExclusion Criteria:\n\n* Long term use of opioids\n* Long term use of NSAIDs\n* Have a history of psychosis, epilepsy, preoperative anxiety, depression, and emotional management disorders\n* Patients with increased gastric contents reflux and respiratory tract aspiration\n* Operation time\\>3h\n* Severe liver and kidney insufficiency, cardiac insufficiency, bradycardia with 2 ° II or 3° atrioventricular block\n* Those who are allergic to or have contraindications to drugs that may be used in the test\n* Those who cannot cooperate with researchers",true,"99 Years",{"count":156,"type":21},160,[158],"PHASE4","To analyze and compare the effect of OFA scheme and traditional balanced anesthesia scheme on QoR15 after thyroidectomy, and further clarify the safety and rationality of OFA scheme in perioperative application of thyroid surgery.",[161],"Opioid-free Anesthesia",[163,164],"thyroidectomy","the early quality of recovery","2026-08-03",{"date":115,"type":32},{"date":168,"type":32},"2024-08-01",{"date":170,"type":21},"2026-12-30",{"name":38,"class":39},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":40},"100650473","retrospective-analysis-of-early-gastric-cancer-patients-based-on-prospective-clinical-dataset-100650473","NCT07747688","Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset","Establishing an Innovative Cohort for Chinese Early Gastric Cancer Patients Based on the National Clinical Research Center for Digestive Diseases Prospective Database: A Retrospective Study","Inclusion Criteria:\n\n* patients aged between 18 and 90 years;\n* preoperative endoscopic biopsy-confirmed gastric adenocarcinoma;\n* clinical stage early gastric (cT1NxM0) cancer according to the AJCC 8th edition TNM staging system;\n* patients who have signed a broad informed consent.\n* Received primary treatment (including endoscopic resection, laparoscopic surgery, open surgery, or combined laparoscopic-endoscopic approach) at Beijing Friendship Hospital.\n\nExclusion Criteria:\n\n* pregnant or breastfeeding women;\n* Preoperative or intraoperative diagnosis remained indeterminate due to insufficient pathological or imaging evidence, such that the patient could not be clearly classified as early gastric cancer prior to treatment;\n* Critical clinical data were severely incomplete or missing；\n* Completely lost to follow-up with no available information to confirm survival status.",{"count":106,"type":21},"The goal of this retrospective observational cohort study is to describe the real-world clinicopathological characteristics, evolving treatment patterns, and long-term oncological outcomes of early gastric cancer (EGC) patients in China, utilizing a large prospective clinical database.\n\nThe main questions it aims to answer are:\n\nHow do different treatment modalities, including endoscopic resection, laparoscopic surgery, open surgery, and combined laparoscopic-endoscopic approaches, influence the long-term survival (Overall Survival and Disease-Free Survival) and recurrence patterns in Chinese EGC patients? What are the key clinicopathological factors affecting prognosis in this population? This study will retrospectively enroll approximately 5000 patients with histopathologically confirmed gastric adenocarcinoma staged as early gastric cancer (per AJCC 8th edition) from the information database of the National Clinical Research Center for Digestive Diseases. Researchers will systematically collect baseline demographics, treatment details, surgical complications, pathological staging, and longitudinal follow-up data (up to 10 years post-surgery) for all eligible patients. By comparing the short-term safety profiles and long-term survival benefits across different treatment groups and identifying risk factors for recurrence, this study aims to provide high-quality, China-specific evidence to guide standardized and individualized clinical decision-making for early gastric cancer.",[57],"2026-07-31",{"date":115,"type":32},{"date":185,"type":32},"2026-05-08",{"date":187,"type":21},"2027-06-08",{"name":38,"class":39},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":52,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100648649","safety-and-efficacy-of-liposomal-amphotericin-b-for-patients-with-invasive-mold-diseases-in-liver-transplant-recipients-100648649","NCT07725874","Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients","Inclusion Criteria:\n\nPatients aged ≥12 years. Liver transplant recipients. Proven or probable invasive mold disease (IMD) according to the 2020 EORTC\u002FMSGERC criteria.\n\nHave received at least one dose of liposomal amphotericin B (AmBisome) or voriconazole.\n\nExclusion Criteria:\n\nHistory of invasive mold disease previously treated with amphotericin B for more than 5 days.\n\nDocumented hypersensitivity or allergy to amphotericin B formulations. Sequential Organ Failure Assessment (SOFA) score \\>15. Expected survival \\\u003C72 hours. Pregnant or breastfeeding. Patients who, in the investigator's judgment, are unable to complete the study treatment or follow the study protocol.\n\nRecipients of combined organ transplantation or multivisceral transplantation.","12 Years",{"count":197,"type":21},60,[54],"Invasive mold diseases (IMD) carry extremely high mortality rates in liver transplant recipients (aspergillosis prevalence \\~1.8%, mortality 60%-90%; mucormycosis prevalence \\~2%, mortality 38%-95%). Guidelines emphasize early antifungal therapy: liposomal amphotericin B (L-AmB) is the first-line choice in liver insufficiency; voriconazole remains the gold standard for aspergillosis (but ineffective against mucormycosis), yet its use is limited by significant drug-drug interactions-requiring a 50%-60% dose reduction of calcineurin inhibitors and contraindicated with sirolimus-thereby increasing the risk of graft rejection. Currently, no head-to-head clinical trials compare voriconazole and L-AmB in liver transplant recipients with IMD. Therefore, a prospective real-world study is planned to generate robust data to support updates to international or Chinese guidelines.",[201],"Invasive Mold Diseases","2026-07-22",{"date":204,"type":32},"2026-07-24",{"date":206,"type":21},"2026-08-08",{"date":208,"type":21},"2028-08-15",{"name":38,"class":39},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":40},"100440438","the-impact-of-immune-cell-changes-during-the-perioperative-period-on-the-prognosis-of-patients-with-colorectal-cancer-100440438","NCT05015296","The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer","A Multicenter, Prospective, Non-interventional Real-world Study of the Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer","Inclusion Criteria:\n\n* 18-85 years old, regardless of gender;\n* Patients with newly diagnosed CRC who are planned to undergo surgery (including patients with metastases but still feasible for surgery);\n* Patients who have not been diagnosed for the first time and have not received surgical treatment and now planned to undergo surgery(e.g., patients after neoadjuvant radiotherapy and chemotherapy for middle and low rectal cancer).\n\nExclusion Criteria:\n\n* Patients who refused to sign informed consent;\n* Patients complicated with other tumors;\n* Pregnant or lactating women;\n* People with a history of psychotropic drug abuse and unable to quit or those with mental disorders;\n* Postoperative histopathological examinations for patients with non-CRC type;\n* Patients who could not be followed up.","85 Years",{"count":219,"type":21},7000,"This is a multi-center, prospective, non-interventional real-world study. In a real-world environment, in line with the current status of the domestic diagnosis and treatment process, and on the premise of not increasing the burden of patients and medical resources, we explore the best indicators for predicting the outcome of patients with Clinical Research Coordinator (CRC) after surgery. The inclusion criteria for patients are perioperative patients with CRC. Real-world data analysis were conducted to determine whether immunization interventions versus non-interventions were able to improve patients' clinical outcomes (OS, PFS).",[222],"Colorectal Cancer",[222,224],"Immune Cells","2026-07-17",{"date":227,"type":32},"2026-07-20",{"date":229,"type":32},"2021-11-23",{"date":231,"type":21},"2030-12-31",{"name":38,"class":39},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":52,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":40},"100626916","digital-rehabilitation-for-gastric-cancer-surgery-after-neoadjuvant-therapy-100626916","NCT07441850","Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy","The Effect of Perioperative Rehabilitation Programme Delivered Via a Smart Phone Based Digital Platform in Patients Undergoing Neoadjuvant Therapy for Gastric Cancer Surgery: Study Protocol for a Randomised Controlled Trial","Inclusion Criteria:\n\n* patients aged between 18 and 70 years;\n* patients with histologically confirmed resectable adenocarcinoma of the oesophago gastric junction or stomach;\n* patients referred by a multidisciplinary team (MDT) for neoadjuvant therapy;\n* patients able to use a smartphone and the digital follow up platform, and willing to comply with regular follow up assessments;\n* patients who provide written informed consent.\n\nExclusion Criteria:\n\n* presence of distant metastasis;\n* severe cardiopulmonary disease or other contraindications precluding completion of the 6MWT or participation in exercise training;\n* concurrent other malignant tumours;\n* suspected recurrent gastric cancer;\n* cognitive impairment, communication barriers, or psychiatric conditions that would prevent compliance with the study procedures;\n* women who are pregnant, lactating, or planning a pregnancy.","70 Years",{"count":242,"type":21},186,[54],"The goal of this clinical trial is to investigate the effects of a perioperative multimodal rehabilitation program on the incidence of postoperative complications and perioperative clinical indexes including functional capacity, nutritional and psychological status in patients with gastric cancer undergoing neoadjuvant therapy. Besides the investigators also develop a smart phone based digital platform aiming to evaluate its effectiveness in improving patient adherence, compared with the conventional telephone supervision approach. The main questions it aims to answer are:\n\n* Can the perioperative multimodal rehabilitation program reduce postoperative complications in patients with gastric cancer undergoing neoadjuvant therapy?\n* Can the smart phone based digital platform improve patients' adherence compared to traditional telephone supervision?\n* Can the perioperative multimodal rehabilitation program improve the perioperative clinical indicators of patients with gastric cancer undergoing neoadjuvant therapy, including functional capacity, nutritional status and psychological condition? The investigators will compare the perioperative multimodal rehabilitation program with the standard treatment alone to determine whether this program has the effects mentioned above.\n\nParticipants will follow the perioperative multimodal rehabilitation program from neoadjuvant therapy through to four weeks after discharge.",[246],"Gastric Cancer",[248,249,250,251,252,253],"Gastric cancer","Neoadjuvant therapy","Digital health","Randomized control trial","Perioperative rehabilitation","Multimodal intervention","2026-07-07",{"date":256,"type":32},"2026-07-09",{"date":258,"type":32},"2026-03-01",{"date":260,"type":21},"2027-04-01",{"name":38,"class":39},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":270,"targetDuration":4,"studyType":52,"phases":272,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":4},"100641505","phase-2-yang-et-al-anti-pd-1ctla-4-dual-immunotherapy-for-larc-100641505","NCT07596290","Yang et al. Anti-PD-1\u002FCTLA-4 Dual Immunotherapy for LARC","Efficacy and Safety of Neoadjuvant Short-Course\u002FLong-Course Radiotherapy Combined With Anti-PD-1\u002FCTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)","RADICAL","Inclusion Criteria:\n\n1. Age between 18 and 80 years; ECOG performance status 0-1;\n2. Histopathologically confirmed rectal adenocarcinoma via colonoscopy; pMMR or MSS phenotype;\n3. Rectal MRI stage II\u002FIII (excluding T4b); distal tumor margin ≤ 12 cm from the anal verge;\n4. Willingness to comply with study procedures; consent to use tissue and blood samples for medical research purposes;\n5. No prior history of radiotherapy, chemotherapy, or immunotherapy;\n6. No immune system diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, hyperthyroidism\u002Fhypothyroidism, ulcerative colitis, autoimmune hemolytic anemia, HIV infection, etc.);\n7. No severe cardiac, pulmonary, hepatic, or renal dysfunction; no jaundice or gastrointestinal obstruction;\n8. No concurrent acute infection;\n9. Baseline laboratory evaluations completed as required, with results obtained within 14 days before randomization, and laboratory values meeting the following criteria (per CTCAE 5.0):\n\n   * White blood cell count ≥ 2000\u002FμL;\n   * Neutrophil count ≥ 1500\u002FμL;\n   * Platelet count ≥ 100×10³\u002FμL;\n   * Hemoglobin ≥ 9.0 g\u002FdL;\n   * Serum creatinine ≤ 1.5×upper limit of normal (ULN) or creatinine clearance \\> 50 mL\u002Fmin (female: creatinine clearance = \\[140 - age (years)\\] × body weight (kg) × 0.85 \u002F (72 × serum creatinine (mg\u002FdL)); male: creatinine clearance = \\[140 - age (years)\\] × body weight (kg) × 1.00 \u002F (72 × serum creatinine (mg\u002FdL)));\n   * AST ≤ 3×ULN, ALT ≤ 3×ULN, total bilirubin ≤ 1.5×ULN;\n10. No psychiatric\u002Fpsychological disorders affecting social function;\n11. Negative serum pregnancy test (blood HCG) within 1 week before randomization for women of childbearing potential;\n12. Women of childbearing potential must agree to use effective contraception during the study period and for 5 months after the last dose of study drug;\n13. Male subjects who are sexually active with women of childbearing potential must agree to use effective contraception during the study period and for 7 months after the last dose of study drug, and must refrain from sperm donation during this period.\n\nExclusion Criteria:\n\n1. Multiple primary cancers or concurrent other malignant tumors;\n2. Patients requiring emergency surgery due to intestinal obstruction, intestinal perforation, gastrointestinal bleeding, etc.;\n3. Factors affecting oral drug absorption (e.g., inability to swallow, nausea\u002Fvomiting, diarrhea, intestinal obstruction, etc.);\n4. Any uncontrolled, severe concomitant diseases;\n5. Hypersensitivity to any component of the study drugs;\n6. Expected survival \\\u003C 5 years for any reason;\n7. Planned or previous organ\u002Fbone marrow transplantation;\n8. Treatment with immunosuppressants or corticosteroids within 1 month before enrollment;\n9. Central nervous system disorders that may impair ability to provide informed consent or comply with study procedures, as determined by the investigator;\n10. Other conditions that may prevent completion of study treatment (e.g., alcoholism, drug addiction, etc.);\n11. Pregnant or breastfeeding women.",{"count":271,"type":21},342,[273,274],"PHASE2","PHASE3","This is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A total of 342 pMMR\u002FMSS LARC patients will be enrolled and randomly assigned in a 1:1:1 ratio to short-course radiotherapy (5×5Gy) followed by sequential dual immunotherapy (paromlimab + tuvonralimab + CAPEOX), long-course radiotherapy followed by sequential dual immunotherapy, or conventional long-course chemoradiotherapy. The primary endpoint is the complete response rate (pCR + cCR). Secondary endpoints include the proportion of patients adopting the \"watch-and-wait\" strategy, disease-free survival, overall survival, and safety. This study innovatively explores the synergistic mechanism of different radiotherapy fractionations with dual immunotherapy, optimizes the timing of immunotherapy initiation, and constructs a clinical-imaging-pathology multimodal efficacy prediction model, aiming to advance LARC treatment from empirical to precision therapy while achieving organ and function preservation.",[277,278,279],"Locally Advanced Rectal Adenocarcinoma","Neoadjuvant Chemoradiation","Neoadjuvant Immunotherapy",[281,282,283,284,285],"Locally advanced rectal cancer","Neoadjuvant chemoradiation","Anti-PD-1\u002FCTLA-4 Dual Immunotherapy","Short-course radiotherapy","Long-course rediotherapy","2026-06-16",{"date":288,"type":32},"2026-06-17",{"date":290,"type":21},"2026-07-15",{"date":231,"type":21},{"name":38,"class":39},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":153,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":40},"100643367","real-world-data-linkage-research-platform-100643367","NCT07635355","Real-World Data Linkage Research Platform","Inclusion Criteria:\n\n* Participants will be eligible for inclusion if they meet all of the following criteria:\n\n  1. Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status.\n  2. Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information.\n  3. Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources.\n\nExclusion Criteria:\n\n* Participants or records meeting any of the following criteria will be excluded:\n\n  1. Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information).\n  2. Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events.\n  3. Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).",{"count":300,"type":21},300000,"This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.\n\nIn parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.\n\nOverall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.",[303,304],"Chronic Diseases","Sub-optimal Health",[306,307,308,309,310],"Real-world data","Intelligent data governance","confidential computation","trusted data matrix","chronic diseases","2026-06-03",{"date":313,"type":32},"2026-06-09",{"date":315,"type":21},"2026-05-30",{"date":231,"type":21},{"name":38,"class":39},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":17,"minAge":324,"maxAge":49,"enrollmentInfo":325,"targetDuration":4,"studyType":52,"phases":327,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":40},"100640314","standardized-study-protocol-of-percutaneous-vertebroplasty-based-on-pedicle-nine-grid-zoning-method-100640314","NCT07616583","Standardized Study Protocol of Percutaneous Vertebroplasty Based on Pedicle Nine-Grid Zoning Method","Inclusion Criteria:\n\n* Diagnosed with single-segment acute osteoporotic lumbar vertebral compression fracture (L1-L5), confirmed by typical MRI manifestations: low signal on T1-weighted imaging and high signal on T2-weighted and STIR sequences.\n* First-time reception of percutaneous vertebroplasty (PVP) surgery.\n* Complete preoperative imaging data including X-ray, CT, and MRI\u002Fbone scan.\n* Aged patients who voluntarily participate in the study and sign written informed consent.\n\nExclusion Criteria:\n\n* Patients with old vertebral compression fractures or congenital pedicle dysplasia and lesions.\n* With a history of bone tumors or other systematic bone metabolic diseases.\n* CT examination shows incomplete or ruptured posterior wall of the fractured vertebral body.\n* Failure to obtain signed informed consent.","50 Years",{"count":326,"type":21},68,[54],"The goal of this clinical trial is to verify the safety and efficacy of the pedicle \"Nine-grid Zoning Method\" in assisting percutaneous vertebroplasty (PVP) for the treatment of lumbar osteoporotic vertebral compression fractures (OVCF) in adults. It also aims to standardize the puncture path of PVP and optimize the intraoperative operation process. The main questions it aims to answer are:\n\n* Does the \"Nine-grid Zoning Method\" significantly increase the rate of achieving ideal intraoperative puncture endpoints and reduce operative time compared with the traditional pedicle puncture method?\n* Does the novel puncture method reduce intraoperative fluoroscopy times, radiation exposure, and the incidence of postoperative bone cement leakage without increasing surgical risks? Researchers will compare the modified PVP assisted by the \"Nine-grid Zoning Method\" (experimental group) with conventional PVP adopting the traditional \"10 o'clock\u002F2 o'clock\" pedicle puncture point (control group) to confirm the clinical superiority and safety of the new standardized puncture path.\n\nParticipants will:\n\n* Receive unilateral transpedicular PVP surgery via either the nine-grid zoning puncture path or the traditional puncture path for single-segment acute lumbar OVCF\n* Complete preoperative baseline examinations including bone density detection, VAS pain score, ODI functional score and SF-36 quality of life score assessment\n* Receive standardized intraoperative data recording covering operative time, fluoroscopy frequency, radiation dose, bone cement filling and leakage conditions\n* Undergo postoperative follow-up at 1 day after surgery, discharge, 3 months, 6 months and 1 year after operation, with regular imaging re-examination and scale evaluation to monitor fracture recovery and postoperative complications",[330,331],"Osteoporotic Vertebral Compression Fractures","Vertebroplasty",[333,334,335,336],"Nine-grid Area Division Method","PVP","OVCF","Vertebral pedicle puncture","2026-05-27",{"date":339,"type":32},"2026-06-01",{"date":341,"type":32},"2024-01-01",{"date":343,"type":21},"2026-12-31",{"name":38,"class":39},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":354,"studyType":22,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":40},"100640747","prediction-model-of-colorectal-adenoma-recurrence-carcinogenesis-risk-with-tcm-wm-multimodal-feature-fusion-100640747","NCT07611266","Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion","Study on the Prediction Model of Recurrence and Carcinogenesis Risk of Colorectal Adenoma Based on the Fusion of Traditional Chinese and Western Medicine Multimodal Features","Inclusion Criteria:\n\n* Meet the diagnostic criteria for colorectal adenoma (Western medicine) and the relevant TCM syndromes.\n* Aged 18 years or older.\n* Willing to undergo regular follow-up examinations (including colonoscopy and laboratory tests) and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History of Crohn's disease, ulcerative colitis, or other malignancies.\n* Previous history of radiotherapy, chemotherapy, or gastrointestinal surgery.\n* Hereditary polyposis syndromes (e.g., familial adenomatous polyposis, MUTYH-associated polyposis, or hamartomatous polyposis syndrome).\n* Severe cognitive impairment, dementia, or mental illness.\n* Severe cardiovascular or cerebrovascular diseases, or hematological system disorders.",{"count":353,"type":21},3000,"18 Months","This project focuses on developing a risk prediction model for the recurrence and malignant transformation of colorectal adenomas by integrating multimodal features from both Traditional Chinese Medicine (TCM) and Western medicine. Led by Dr. Wei Hongtao from Beijing Friendship Hospital, Capital Medical University, the primary objective is to mine clinical characteristics from both medical systems to construct a robust predictive model. The research encompasses several key aspects: a multicenter, large-sample cohort study design with a clearly defined sample size and calculation basis; patient recruitment from multiple institutions nationwide to form training and validation sets; and strict adherence to standardized TCM and Western diagnostic criteria. Through comprehensive observation of demographic, TCM clinical (e.g., syndromes, tongue and pulse diagnosis), and Western clinical features, the study ensures data accuracy via rigorous monitoring and follow-up. Various algorithms are employed to extract and analyze these multi-source features-including endoscopic data-to build and evaluate the prediction model. Furthermore, the study aims to identify dominant subgroups to optimize TCM intervention strategies. Key performance indicators include establishing the risk model, identifying target populations, publishing high-quality papers, and training graduate students. By innovatively constructing this multimodal fusion model, the project provides a novel perspective and evidence-based foundation for the prevention and treatment of colorectal adenomas using TCM.",[357],"Colorectal Cancer Control and Prevention","2026-05-20",{"date":360,"type":32},"2026-05-28",{"date":362,"type":32},"2025-06-01",{"date":364,"type":21},"2028-11-30",{"name":38,"class":39},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":376,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":390,"locationsCount":40},"100636505","rectal-cancer-neoadjuvant-therapy-real-world-study-100636505","NCT07566559","Rectal Cancer Neoadjuvant Therapy-Real World Study","Establishing a Strategy for Selecting Watchful Waiting and Determining the Optimal Timing for Surgery Following Neoadjuvant Therapy","RC-NAT-RWS","Inclusion Criteria:\n\n* The patient is informed and has provided written informed consent;\n* Rectal adenocarcinoma confirmed by colonoscopic biopsy and pathology, meeting the following criteria:\n\n  1. Clinical stage II\u002FIII locally advanced rectal cancer (LARC): cT1-4aN0-2M0;\n  2. The distal edge of the tumor is ≤ 10 cm from the anal verge (measured by MRI);\n  3. No distant metastasis;\n  4. Scheduled to receive neoadjuvant therapy;\n* Age ≥ 18 years, male or female。\n\nExclusion Criteria:\n\n* Presence of distant organ metastasis;\n* Multiple primary colorectal cancers;\n* History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).",{"count":375,"type":21},869,"5 Years","This study aims to utilise a real-world data platform to integrate multi-omics data-including radiomics, gut microbiota, pathological quality control and liquid biopsy-to construct a multidimensional predictive model for the efficacy of rectal cancer treatment following neoadjuvant therapy. By integrating multimodal data, the study aims to accurately assess the efficacy of neoadjuvant therapy and identify patients suitable for a 'watch-and-wait' strategy, thereby achieving tumour control and preserving organ function without the need for surgery. Furthermore, it seeks to provide scientific evidence for the efficacy of the 'watch-and-wait' strategy and the selection of optimal timing for surgery, whilst validating the model's effectiveness and assessing its clinical feasibility through prospective clinical trials.",[379],"Rectal Cancer",[381,382,383],"Rectal cancer","Real world study","Neoadjuvant Therapy","2026-04-27",{"date":386,"type":32},"2026-05-05",{"date":388,"type":32},"2025-01-01",{"date":36,"type":21},{"name":38,"class":39},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":52,"phases":401,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":40},"100620135","phase-2-adebrelimab-plus-apatinib-combined-with-sox-regimen-as-conversion-therapy-for-gastric-cancer-100620135","NCT07353684","Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer","Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment, with an estimated life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.\n* Unresectable locally advanced gastric or gastroesophageal junction adenocarcinoma (Stage III or IV), as determined by the investigator based on CT, MRI, and\u002For PET-CT.\n* Disease with conversion (translational) therapeutic potential, as assessed by the investigator.\n* No prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic anticancer therapies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate hematologic function within 14 days prior to enrollment:\n\n  * White blood cell count ≥ 3.5 × 10⁹\u002FL.\n  * Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL.\n  * Hemoglobin ≥ 90 g\u002FL (9.0 g\u002FdL).\n  * Platelet count ≥ 100 × 10⁹\u002FL.\n  * Adequate hepatic function within 14 days prior to enrollment:Total bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2.5 × ULN in patients without liver metastases;ALT and AST ≤ 5 × ULN in patients with liver metastases;Adequate renal function:Serum creatinine ≤ 1.5 × ULN;Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 12 weeks after the last dose.\n* Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose\n* Ability to understand and willingness to sign a written informed consent form\n* Expected to comply with study procedures and follow-up requirements\n\nExclusion Criteria:\n\n* HER2-positive gastric or gastroesophageal junction adenocarcinoma.\n* Conditions that may significantly affect oral drug absorption, including inability to swallow, persistent nausea or vomiting, chronic diarrhea, or intestinal obstruction.\n* Known hypersensitivity or allergy to adebrelimab, apatinib, oxaliplatin, S-1 (tegafur\u002Fgimeracil\u002Foteracil), or any of their excipients.\n* History of severe allergic reactions to monoclonal antibodies.\n* Active autoimmune disease or autoimmune disorders requiring systemic treatment.\n* Congenital or acquired immunodeficiency.\n* Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.\n* Administration of live attenuated vaccines within 4 weeks prior to the first dose or planned during the study period.\n* Severe infection within 4 weeks prior to initiation of study treatment.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Evidence of interstitial lung disease, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severely impaired pulmonary function.\n* Uncontrolled hypertension despite at least 3 months of antihypertensive treatment.\n* Uncontrolled clinically significant cardiovascular disease.\n* High risk of severe bleeding, as judged by the investigator.\n* Peripheral neuropathy of Grade \\> 2 according to CTCAE.\n* Participation in another interventional clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for study participation.","75 Years",{"count":400,"type":21},49,[273],"This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be enrolled in this study. All participants will be treated with 2 to 8 cycles of adebrelimab, apatinib, oxaliplatin, and tigio before surgery. Participants will evaluate the treatment effect after every 2 cycles of medication. By the investigator assessment as an operable subject, apatinib was discontinued for one cycle. The adjuvant treatment will be determined by the investigators based on the participants' postoperative pathology results. Participants requiring adjuvant therapy, with a postoperative interval of at least 4 weeks, but not more than 10 weeks. When the resection standard isn't met for 8 cycles of treatment, the treatment is switched to a maintenance phase, which the subject treatment regimen is determined by the investigator. During the treatment period, participants will receive the study drugs on Day 1 of each 21-day cycle until evidence of disease progression or unacceptable toxicity.",[404,405,406],"Adebrelimab","Adenocarcinoma of GE Junction","Adenocarcinoma of Stomach",[408,409,410,411],"adebrelimab","Adenocarcinoma of GE junction","Adenocarcinoma of stomach","conversion therapy","2026-04-21",{"date":414,"type":32},"2026-04-22",{"date":416,"type":32},"2025-05-11",{"date":418,"type":21},"2028-05-31",{"name":38,"class":39},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":398,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":40},"100623162","application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer-100623162","NCT07393048","Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer","ctDNA-MRD-RC","Inclusion Criteria:\n\n* 1: Signed a written informed consent form and voluntarily participated in this study\n* 2: Aged 18-75 years, regardless of sex\n* 3: Histopathologically confirmed rectal adenocarcinoma\n* 4: Clinical stage II-III as assessed by MRI (according to the AJCC 8th edition)\n* 5: Distance from the lower tumor margin to the anal verge ≤10 cm\n* 6: Surgically resectable\n* 7: Able to swallow tablets normally\n* 8: ECOG PS 0-1\n* 9: No prior antitumor therapy for rectal cancer, including radiotherapy, chemotherapy, or surgery\n* 10: Scheduled to undergo surgical treatment after completion of neoadjuvant therapy\n* 11: No surgical contraindications\n* 12: Normal function of major organs, including: complete blood count, blood biochemistry, and coagulation function\n\nExclusion Criteria:\n\n* 1: History of allergy to monoclonal antibodies, any component of tislelizumab, or capecitabine\n* 2: Prior or ongoing receipt of any tumor-directed surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc\n* 3: Presence of any active autoimmune disease or history of autoimmune disease\n* 4: History of immunodeficiency, including a positive HIV test result, other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation\n* 5: Poorly controlled cardiac clinical symptoms or diseases, including but not limited to: heart failure of NYHA class II or above, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia that remains poorly controlled without or despite clinical intervention\n* 6: Diagnosis of another malignancy within 5 years prior to the first use of the study drug, except for malignancies with low risk of metastasis or death (5-year survival rate \\>90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, which may be considered for inclusion\n* 7: Pregnant or lactating women\n* 8: Other factors, as judged by the investigator, that may lead to premature termination of the study, such as other severe diseases (including psychiatric disorders) requiring concomitant treatment, alcohol abuse, drug abuse, family or social factors, or any condition that may affect the safety or compliance of the participant",{"count":197,"type":21},"This study is a single-center, prospective, observational clinical trial enrolling patients with locally advanced rectal cancer (cT3-4aN0M0 and cT1-4aN1-2M0). By collecting tissue and blood samples at multiple timepoints, and integrating multi-omics data including ctDNA mutations, copy number variations, and mtDNA profiles, a multi-omics model will be constructed to predict the efficacy of neoadjuvant therapy for rectal cancer.",[430],"Locally Advanced Rectal Cancer (LARC)",[432,379,383,433,434],"ctDNA-MRD","Predicting the Efficacy","Detection Technology","2026-04-20",{"date":412,"type":32},{"date":438,"type":32},"2026-02-15",{"date":36,"type":21},{"name":38,"class":39},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":52,"phases":450,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":40},"100616995","phase-1-safety-and-tolerability-study-of-a-novel-bioartificial-liver-in-liver-failure-and-small-for-size-syndrome-100616995","NCT07312864","Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome","A Clinical Trial Assessing the Safety, Tolerability, and Exploratory Efficacy of a Novel Bioartificial Liver Therapy in Patients With Liver Failure or Small-for-Size Syndrome","Inclusion Criteria:\n\n* Patients diagnosed with liver failure (including acute, subacute\u002Facute-on-chronic, and chronic liver failure) or small-for-size syndrome\n\nExclusion Criteria:\n\n* Presence of severe extrahepatic systemic end-stage diseases\n* Uncontrollable infection or active bleeding\n* Pregnant or breastfeeding women\n* History of allergy or known severe hypersensitivity to CiPSC-derived cell products or blood products\n* Peripheral vascular collapse leading to inability to obtain venous access or collect blood\n* Unable or unwilling to provide informed consent or unable to comply with study requirements\n* Unwilling to receive CiPSC-based therapy",{"count":449,"type":21},12,[451,273],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of a novel bioartificial liver (CiPS-BAL) in patients with liver failure or small-for-size syndrome. The study will also collect preliminary data on clinical outcomes and laboratory parameters during treatment. The main questions it aims to answer are:\n\nIs the novel bioartificial liver system safe and well tolerated in patients with liver failure or small-for-size syndrome?\n\nWhat effects does the treatment have on liver function and other clinical and laboratory indicators?\n\nResearchers will treat participants with the CiPS-BAL system, which uses hepatocytes derived from chemically induced pluripotent stem cells (CiPS) within a bioartificial liver device.",[454,455],"Liver Failure","Small-for-Size Syndrome","2026-04-15",{"date":435,"type":32},{"date":459,"type":32},"2025-12-01",{"date":36,"type":21},{"name":38,"class":39},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":153,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":4},"100634589","study-on-eye-brain-cross-organ-mapping-and-systemic-disease-association-based-on-multimodal-big-data-100634589","NCT07541651","Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data","Inclusion Criteria:\n\n* Eye data: Images must meet quality standards (no significant artifacts, key structures clearly visible), with complete examination records (including examination date and device model).\n* Brain data: MR images must be free of motion artifacts, with complete sequences (at least including T1-weighted imaging and MRA), and reports must confirm no technical issues.\n* Eye-brain paired cohort: Must contain at least one type of eye image (including CFP, OCT, or OCTA) along with brain MR data, and be linkable to a unique identifier and clinical information in the database\n* Clinical data: Clinical information (such as core biochemical indicators, demographic information, and necessary questionnaire items) must have a missing rate ≤30%, with standardized and clear ICD diagnostic codes, complete laboratory test data, and medical order information (including medication or follow-up recommendations)\n* Prior to initial inclusion in the study, participants must have no history of severe organic diseases (including non-curable or end-stage malignancies, severe heart failure (NYHA Class III-IV), end-stage renal disease (CKD Stage 5), decompensated cirrhosis, or significant functional impairment due to severe cerebrovascular disease sequelae, etc.).\n\nExclusion Criteria:\n\n* Ocular examinations in which key features cannot be identified due to conditions such as cataracts or vitreous hemorrhage brain MR images deemed unacceptable in quality due to factors such as metal implants\n* Clinical information (including core biochemical indicators, demographic details, essential questionnaire items, etc.) with a missing rate exceeding 30%\n* Individuals who are pregnant or lactating, those with ocular trauma, congenital ocular malformations, or severe organic diseases.",{"count":469,"type":21},208000,"This project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brain-systemic disease association model. It aims to clarify the quantitative associations between multimodal ocular features and brain structural and vascular characteristics as well as systemic disease ICD diagnoses, thereby uncovering the cross-organ and cross-modal linkage mechanisms between the eye and brain. Ultimately, it seeks to achieve mapping and prediction of brain imaging features based on ocular data, enable ocular-based diagnosis and prediction of various diseases, and contribute significantly to early disease screening, risk stratification, and optimization of clinical diagnosis and treatment.",[472,473,474,475,476],"Cataract","Vitreous Hemorrhage","Diabetic Eye Diseases","Cerebral Small Vessel Disease","Cerebrovascular Stenosis","2026-04-14",{"date":412,"type":32},{"date":480,"type":21},"2026-04-25",{"date":482,"type":21},"2029-12-31",{"name":38,"class":39},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":398,"enrollmentInfo":491,"targetDuration":4,"studyType":52,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":40},"100627840","phase-1-novel-calcium-channel-modulators-in-rls-and-variants-efficacy--safety-100627840","NCT07453862","Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety","Observation of Efficacy and Safety of Novel Calcium Channel Modulators in the Treatment of Restless Legs Syndrome and Its Variant Subtypes","Inclusion Criteria:\n\n* 1\\. Aged 18-75 years, regardless of gender.\n* 2\\. Meets the diagnostic criteria for typical Restless Legs Syndrome (RLS) (IRLSSG criteria) or variant RLS confirmed by a neurologist.\n* 3\\. Moderate to severe RLS (IRLS score ≥11).\n* 4\\. Able to understand and comply with the study protocol, and provides written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Secondary RLS (e.g., iron deficiency anemia with serum ferritin \\\u003C30μg\u002FL, renal dysfunction with eGFR \\\u003C30ml\u002Fmin, pregnancy\u002Flactation, drug-induced RLS with unadjustable medications).\n* 2\\. Severe central nervous system diseases (e.g., status epilepticus, severe dementia, stroke within 3 months).\n* 3\\. Severe cardiovascular diseases (e.g., congestive heart failure, uncontrolled hypertension with SBP≥180mmHg or DBP≥110mmHg).\n* 4\\. Severe liver or kidney dysfunction (ALT\u002FAST \\>3×ULN, eGFR \\\u003C30mL\u002Fmin\u002F1.73m²).\n* 5\\. Active mental illnesses (e.g., schizophrenia, acute bipolar disorder).\n* 6\\. Hypersensitivity to Keligabalin Benzenesulfonic Acid or its excipients.\n* 7\\. Participation in other clinical trials within 1 month, inability to cooperate with follow-up, or history of substance abuse.\n* 8\\. Pregnancy or lactation.",{"count":492,"type":21},20,[451],"The goal of this \\[study type: clinical trial\\] is to \\[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\\] in \\[describe participant population\u002Fprimary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\\]. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\n* Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period?\n* What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients?\n\nParticipants will \\[describe the main tasks participants will be asked to do, interventions they'll be given\\]:\n\n* Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks\n* Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion",[496,497],"Restless Leg Syndrome (RLS)","Variant Restless Legs Syndrome","2026-03-03",{"date":500,"type":32},"2026-03-06",{"date":502,"type":21},"2026-03-10",{"date":504,"type":21},"2027-08-31",{"name":38,"class":39},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":4},"100627593","hepatic-and-splenic-microcirculatory-perfusion-for-ruling-out-high-risk-varices-in-patients-with-hepatitis-b-related-cirrhosis-100627593","NCT07450651","Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis","Development of a Hepato-Splenic Microcirculatory Perfusion Model Using IVIM MRI to Rule Out High-Risk Varices in Patients With Compensated Hepatitis B-Related Cirrhosis","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Clinically diagnosed with chronic hepatitis B cirrhosis\n3. Acceptance of upper gastrointestinal endoscopy screening or evaluation.\n4. Abdominal MRI examination with IVIM sequence within 6 months prior to endoscopy.\n\nExclusion Criteria:\n\n1. Co-existing chronic liver diseases.\n2. Previous portosystemic shunt treatment or splenectomy.\n3. A history of treatment for upper gastrointestinal varices that affects the assessment.\n4. Severe hepatic or splenic iron deposition.\n5. Decompensated cirrhosis.\n6. Co-existing malignancies.",{"count":514,"type":21},150,"Background:\n\nChronic hepatitis B (CHB)-related cirrhosis is a common cause of portal hypertension, which leads to the development of gastroesophageal varices (EGVs). High-risk varices (HRV) are associated with a higher risk of bleeding and require timely interventions. Endoscopy is the gold standard for diagnosing HRV but is invasive and not suitable for routine screening in large populations.\n\nObjective:\n\nThis study aims to develop a noninvasive model based on hepatic and splenic microcirculatory perfusion parameters derived from intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI) to predict and rule out HRV in patients with compensated CHB-related cirrhosis receiving antiviral therapy.\n\nMethods:\n\nThis observational, retrospective study will include patients with compensated CHB-related cirrhosis who have undergone both esophagogastroduodenoscopy (EGD) and IVIM MRI. Microcirculatory perfusion parameters will be extracted from IVIM images using a biexponential model, and their ability to predict HRV will be assessed.\n\nOutcomes:\n\nThe study will validate the performance of the Hepato-Splenic Microcirculatory Perfusion Model (HSMP) in ruling out HRV compared to conventional noninvasive tests like APRI, FIB-4, and LSM. The model's diagnostic accuracy will be evaluated with a focus on reducing unnecessary endoscopic procedures.\n\nSignificance:\n\nIf successful, this model could reduce the need for invasive endoscopy and improve the management of cirrhosis patients by providing a safer and more accessible screening tool for HRV.",[517,518,519],"Hepatitis B Virus Related Cirrhosis","Portal Hypertension Related to Cirrhosis","Esophagogastric Varices",[521,522,523,524,525,526,527],"Intravoxel incoherent motion","Hepatic microcirculation","Splenic microcirculation","High-risk varices","Baveno VI criteria","FIB-4","Liver stiffness measurement",{"date":529,"type":32},"2026-03-05",{"date":531,"type":21},"2026-02",{"date":533,"type":21},"2026-10",{"name":38,"class":39},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":543,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":52,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":559,"leadSponsor":560,"locationsCount":40},"100530845","adverse-cardiovascular-events-during-painless-gastroscopy-diagnosis-and-treatment-in-elderly-frail-patients-100530845","NCT06192082","Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients","Clinical Study About Impacts of Anesthesia Methods on Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients","frail","Inclusion Criteria:\n\n1. Age greater than 65 years old, regardless of gender\n2. ASA is classified as Class II and III;\n3. BMI 18-28 kg\u002Fm2;\n4. Patients undergoing examination or treatment outside the operating room;\n5. FRAIL scale score ≥ 3 points 6 The patient voluntarily participated in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1 Those who are allergic or contraindicated to drugs such as benzodiazepines, opioids, propofol, and their drug components;\n\n2\\. Acute heart failure; Unstable angina pectoris; Myocardial infarction occurred within 6 months prior to screening; Resting electrocardiogram heart rate\\\u003C50 beats\u002Fminute; Third degree atrioventricular transmission delay; Severe arrhythmia; Moderate to severe heart valve disease;\n\n3\\. Patients with severe respiratory diseases (acute respiratory infections, acute exacerbations of chronic obstructive pulmonary disease, uncontrolled asthma, etc.);\n\n4\\. Patients who have not received formal antihypertensive treatment or have poor blood pressure control;\n\n5\\. Patients with traumatic brain injury, possible presence of intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents, and central nervous system diseases;\n\n6\\. Individuals with mental system diseases (schizophrenia, mania, bipolar disorder, mental disorder, etc.), long-term history of taking psychotropic drugs, and cognitive impairment;\n\n7\\. Other situations that have been determined by the researcher to be unsuitable for inclusion.","65 Years","100 Years",{"count":546,"type":21},226,[54],"This study aims to compare the effects of conscious sedation and intravenous general anesthesia on cardiovascular events in frail patients undergoing digestive endoscopy diagnosis and treatment.",[550],"Anesthesia",[552,553,554],"gastroscopy","frail patients","adverse cardiovascular events","2026-02-11",{"date":557,"type":32},"2026-02-12",{"date":341,"type":32},{"date":557,"type":21},{"name":38,"class":39},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":398,"enrollmentInfo":568,"targetDuration":4,"studyType":52,"phases":570,"briefSummary":571,"conditions":572,"keywords":576,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":587,"locationsCount":40},"100623500","phase-2-short-course-radiotherapy-combined-with-chemotherapy-and-immunotherapy-in-mid-low-locally-advanced-rectal-cancer-100623500","NCT07397442","Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","A Prospective, Phase II, Single-Arm Study on the Efficacy and Safety of Neoadjuvant Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. ECOG performance status score 0-2.\n3. Rectal adenocarcinoma confirmed by colonoscopic pathology, with pMMR or MSS.\n4. Imaging studies confirm no distant metastasis or lateral lymph node metastasis; MRI staging is II\u002FIII (excluding T4b, N1c, N2) and any positive lymph nodes (if present) are confined within the mesorectum.\n5. MRI shows the distal margin of the tumor is ≤10 cm from the anal verge, and the mesorectal fascia (MRF) is negative.\n6. The longest diameter of the rectal cancer lesion is ≥10 mm on baseline CT or MRI (meeting the definition of a \"measurable lesion\" per RECIST 1.1 criteria).\n7. Willing and able to comply with the study procedures.\n8. Consent to the use of tissue and blood samples by the investigator for medical research purposes.\n9. No prior history of radiotherapy or immunotherapy.\n10. No history of immune system diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, ulcerative colitis, HIV infection, etc.).\n11. No history of endocrine system diseases (e.g., hyperthyroidism, hypothyroidism, thyroid nodules, thyroiditis, type 1 diabetes, type 2 diabetes, gestational diabetes, other specific types of diabetes, Cushing's syndrome, primary aldosteronism, pheochromocytoma, adrenal insufficiency, pituitary adenoma, anterior pituitary hypofunction, acromegaly, gigantism, polycystic ovary syndrome, precocious puberty, hypogonadism, hyperparathyroidism, hypoparathyroidism, etc.).\n12. No severe cardiac, pulmonary, hepatic, or renal dysfunction.\n13. No jaundice or gastrointestinal obstruction.\n14. No concurrent acute infection.\n15. Subjects must undergo all required baseline laboratory assessments, and results must be obtained within 1 week before enrollment. Laboratory values must meet the following criteria (per CTCAE 5.0):\n\n    1. White blood cell count ≥2000\u002FμL.\n    2. Neutrophil count ≥1500\u002FμL.\n    3. Platelet count ≥100×10³\u002FμL.\n    4. Hemoglobin ≥9.0 g\u002FdL.\n    5. Creatinine: serum creatinine ≤1.5 × upper limit of normal (ULN) or creatinine clearance \\>50 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n    6. Creatinine clearance for females = \\[140 - age (years)\\] × weight (kg) × 0.85 ÷ \\[72 × serum creatinine (mg\u002FdL)\\].\n    7. Creatinine clearance for males = \\[140 - age (years)\\] × weight (kg) × 1.00 ÷ \\[72 × serum creatinine (mg\u002FdL)\\].\n    8. Aspartate aminotransferase (AST) ≤3 × ULN, alanine aminotransferase (ALT) ≤3 × ULN, total bilirubin ≤1.5 × ULN.\n16. No psychiatric\u002Fpsychological disorders affecting social functioning.\n17. Women of childbearing potential must have a negative serum pregnancy test (blood HCG) within 1 week before enrollment.\n18. Women of childbearing potential and men who are sexually active with women of childbearing potential must agree to use appropriate contraceptive methods.\n\nExclusion Criteria:\n\n1. Multifocal cancer, or concomitant other malignant tumors.\n2. Received any anti-tumor therapy for other malignant tumors within the past 5 years.\n3. Underwent major surgery recently (within 6 months).\n4. Presence of multiple factors affecting oral drug absorption (e.g., inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).\n5. Any uncontrolled, severe comorbid diseases.\n6. Allergy to any component of the study medication.\n7. Life expectancy less than 5 years for any reason.\n8. Planning to undergo or previously underwent organ\u002Fbone marrow transplantation.\n9. Received immunosuppressive agents or glucocorticoid therapy aimed at suppressing immune responses within 1 month before enrollment.\n10. For patients with a history of central nervous system diseases, the investigator will determine whether their current condition allows them to provide informed consent or comply with the study procedures, and subsequently decide whether they can be enrolled.\n11. Other diseases or conditions that may prevent completion of the study treatment (e.g., alcoholism, drug addiction, etc.).\n12. Pregnant or lactating women.",{"count":569,"type":21},19,[273],"The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs). The study aims to increase the chance of making the tumor disappear completely (called \"complete response\") and improve the quality of life by increasing the rate of anal sphincter preservation (avoiding permanent colostomy bags).\n\nThe main questions it aims to answer are:\n\nDoes the combination of short-course radiation therapy, two types of immunotherapy drugs (Qibeian and Aike), and chemotherapy (XELOX) increase the complete response rate to over 50%? Is this combination treatment safe, and what are the side effects? Can this treatment help more patients keep their anal function and avoid permanent stomas?\n\nThis is a single-arm study, meaning all participants will receive the experimental treatment (there is no placebo or control group).\n\nParticipants will:\n\nReceive short-course radiation therapy (25 Gy total, given once daily for 5 consecutive days). The radiation will target only the tumor and visible lymph nodes, intentionally avoiding unaffected lymph node areas to protect the immune system.\n\nReceive Qibei'an (a dual immunotherapy drug targeting both PD-1 and CTLA-4) once, 2 days after completing radiation.\n\nReceive Camrelizumab (a PD-1 immunotherapy drug) three times, combined with XELOX chemotherapy.\n\nReceive XELOX chemotherapy (Oxaliplatin ivgtt on Day 1, plus Capecitabine pills taken twice daily for 14 days, for each cycle) for up to 3 cycles.\n\nUndergo detailed assessments after treatment, including MRI scans, colonoscopy with biopsies, and blood tests (including ctDNA tests), to determine if the tumor has disappeared or if surgery is needed.\n\nAttend regular follow-up visits for up to 5 years after treatment (or surgery) to monitor for recurrence and assess quality of life.\n\nThe study will enroll approximately 19 patients at Beijing Friendship Hospital, Capital Medical University. An independent safety monitoring board will regularly review the data to ensure participant safety.",[573,574,575],"Rectal Cancer, Adenocarcinoma","Rectal Cancer Stage II","Rectal Cancer Stage III",[577,578,579,580,581],"locally advanced rectal cancer","short-course radiotherapy","anti-PD1","anti-CTLA4","complete response","2026-02-09",{"date":555,"type":32},{"date":258,"type":21},{"date":586,"type":21},"2033-02-28",{"name":38,"class":39},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":595,"targetDuration":4,"studyType":52,"phases":597,"briefSummary":598,"conditions":599,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":40},"100624038","phase-4-rivaroxaban-in-idiopathic-membranous-nephropathy-100624038","NCT07404436","Rivaroxaban in Idiopathic Membranous Nephropathy","Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial","Inclusion Criteria:\n\nAge 18-80 years, either sex. Kidney biopsy findings on both light microscopy and electron microscopy consistent with idiopathic membranous nephropathy (IMN).\n\nIMN patients at high risk of thrombosis: meeting the diagnostic criteria for nephrotic syndrome and having serum albumin \\\u003C25 g\u002FL. Normal renal function (normal creatinine clearance).\n\nExclusion Criteria:\n\nPrior thrombotic events, such as pulmonary embolism, renal vein thrombosis, or lower-extremity deep vein thrombosis.\n\nPulmonary diseases that may affect the accuracy of ventilation-perfusion (V\u002FQ) scanning for diagnosing pulmonary embolism, such as pulmonary infection\u002Finflammation, lung tumors, or chronic obstructive pulmonary disease.\n\nInability to undergo V\u002FQ scanning, e.g., right-to-left congenital cardiac shunt, prior allergy to radiopharmaceuticals, or inability to cooperate with the examination.\n\nClinically significant active bleeding. Pregnant or breastfeeding women. Acute myocardial infarction and\u002For acute stroke, or atrial fibrillation. Active infection or active malignancy. Coagulation abnormalities; hepatic dysfunction (aminotransferases ≥3× the upper limit of normal); or thrombocytopenia (platelet count \\\u003C100×10\\^9\u002FL).",{"count":596,"type":21},134,[158],"Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN). IMN patients at high risk of thrombosis and low risk of bleeding will be enrolled and randomly assigned to a rivaroxaban group or a control group (receiving warfarin). Prophylactic anticoagulation will be administered with rivaroxaban or warfarin accordingly. Over the 6 months following initiation of prophylactic anticoagulation, the incidence of the primary efficacy endpoint (a composite of pulmonary embolism, deep vein thrombosis, and lower-extremity deep vein thrombosis) and the safety endpoint (bleeding events) will be compared between the two groups.",[600],"Idiopathic Membranous Nephropathy","2026-02-05",{"date":555,"type":32},{"date":604,"type":32},"2024-01-05",{"date":343,"type":21},{"name":38,"class":39},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":240,"enrollmentInfo":614,"targetDuration":616,"studyType":22,"phases":4,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":629,"locationsCount":40},"100620511","eye-brain-kidney-in-ckd-100620511","NCT07358572","Eye-Brain-Kidney in CKD","A Study on the Eye-Brain-Kidney Interaction Mechanisms in Chronic Kidney Disease Based on Multimodal Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Aged 18-70 years.\n2. Patients clinically diagnosed with CKD stages 1-5.\n3. No contraindications for MRI examination (e.g., cardiac pacemaker, claustrophobia, cochlear implant, hearing aid, coronary stents implanted before 2015) and able to complete the MRI scan.\n\nExclusion Criteria:\n\n1. Patients with recent or prior cerebral hemorrhage or cerebral infarction.\n2. History of epileptic seizures or psychiatric disorders.\n3. Patients with claustrophobia.\n4. Pregnant or lactating patients.\n5. Presence of other central nervous system diseases (e.g., tumor, trauma).\n6. Unstable angina, congestive heart failure (NYHA class III or IV), or acute myocardial infarction.\n7. Any systemic or other diseases deemed unsuitable for clinical trial participation.",{"count":615,"type":21},1500,"3 Years","The goal of this observational study is to learn about the interaction between the eyes, brain, and kidneys in adult patients with Chronic Kidney Disease (CKD). The main question it aims to answer is:\n\nDo changes in the brain's network connectivity and the retina's blood vessels correlate with cognitive decline and kidney function in CKD patients? Participants with CKD who are already undergoing clinical care will complete cognitive tests and questionnaires, have non-invasive MRI scans of their brain and kidneys, and undergo non-invasive eye imaging (OCT\u002FOCTA) of their retinas.",[619],"Chronic Kidney Diseases",[621,622],"Multimodal magnetic resonance imaging","Montreal Cognitive Assessment","2026-01-25",{"date":625,"type":32},"2026-01-27",{"date":459,"type":32},{"date":628,"type":21},"2031-12-31",{"name":38,"class":39},""]